Results 151 to 160 of about 51,509 (201)
Some of the next articles are maybe not open access.
Pharmacology of bisphosphonates
Bone, 2011Four decades of preclinical and clinical research of the pharmacology of bisphosphonates have generated data and concepts that have considerably improved their clinical use. However, despite this progress several pharmacological aspects relevant to bisphosphonate action on bone are still incompletely understood.
Serge Cremers, Socrates Papapoulos
exaly +4 more sources
Bisphosphonates: From Bench to Bedside
Annals of the New York Academy of Sciences, 2006 The discovery and development of the bisphosphonates (BPs) as a major class of drugs for the treatment of bone diseases has been a fascinating journey that is still not over.
Robert Graham G Russell
exaly +2 more sources
Bisphosphonates and Bisphosphonate Induced Osteonecrosis
Oral and Maxillofacial Surgery Clinics of North America, 2007Bisphosphonate-induced osteonecrosis of the jaws is the correct term for this real drug complication that most dental practitioners face. All nitrogen-containing bisphosphonates pose a risk, which is related to the route of administration, the potency of the bisphosphonate, and the duration of use.
Yoh, Sawatari, Robert E, Marx
openaire +2 more sources
Bisphosphonates and Osteoporosis
New England Journal of Medicine, 2002Osteoporosis affects millions of postmenopausal women in the United States alone. For white women who reach 50 years of age, the lifetime risk of vertebral fracture is about one in three, and that for hip fracture is one in six. One tenth to one fifth of the women who have a hip fracture die within a year after it occurs, and one quarter must move ...
openaire +4 more sources
Bone, 2011
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E, Coleman, Eugene V, McCloskey
openaire +2 more sources
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E, Coleman, Eugene V, McCloskey
openaire +2 more sources
Bisphosphonates for Osteoporosis
New England Journal of Medicine, 2010A 67-year-old woman is referred by her primary care physician for treatment of osteoporosis and progressive bone loss. Oral bisphosphonate therapy is recommended. Bisphosphonates suppress bone resorption by interfering with osteoclast activity. Several of these agents have been shown to prevent fractures and increase bone mineral density in patients ...
openaire +2 more sources
Bisphosphonates: Preclinical Aspects and Use in Osteoporosis
Annals of Medicine, 1997 The bisphosphonates are synthetic compounds characterized by a P-C-P bond. They have a strong affinity to calcium phosphates and hence to bone mineral. In vitro they inhibit both formation and dissolution of the latter.
Fleisch HA
exaly +2 more sources
Bisphosphonates and atherosclerosis
General Pharmacology: The Vascular System, 2000Bisphosphonates are used for the treatment of bone resorption, hypercalcemia, osteoporosis and Paget's disease. Etidronate, pamidronate and clodronate also inhibit the development of experimental atherosclerosis without altering serum lipid profile. Bisphosphonates inhibit the arterial calcification, lipid accumulation and fibrosis.
openaire +2 more sources
Bone, 2020
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources